Alex Dejesus
Rheumatology · San Antonio, TXNPI 1013986629
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $49,725 of the $68,122 with a category attached, or 73.0%. Janssen Scientific Affairs, LLC accounts for 62.9% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2019 at $46,393 and has fallen 94.8% since, to $2,396 in 2021. Among rheumatology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 324 payments — averaging $210.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$43K
- AbbVie$17K
- Johnson & Johnson$4K
- Amgen$1K
- E.r. Squibb & Sons, L.L.C.$465
- UCB, Inc.$317
- plus $2K from 19 others
Across 230 payments — averaging $2030.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$272K
- AbbVie$117K
- Sun Pharmaceutical Industries Inc.$44K
- GSK$15K
- Dr.reddy's Laboratories,inc.$11K
- Pfizer$5K
- plus $3K from 3 others
What the payments were for
- Consulting fees$3,7506%
- Speaking & faculty fees$49,72573%
- Travel & lodging$8,39212%
- Food & beverage$6,2439%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 27 | $42,859 |
| AbbVie | 64 | $17,165 |
| Johnson & Johnson | 18 | $4,028 |
| Amgen(2 entities) | 78 | $1,256 |
| E.r. Squibb & Sons, L.L.C. | 25 | $465 |
| UCB, Inc. | 17 | $317 |
| Mallinckrodt Hospital Products Inc. | 5 | $311 |
| Novartis | 17 | $259 |
| Sanofi | 10 | $184 |
| GSK | 10 | $180 |
| Genentech USA, Inc. | 6 | $165 |
| Radius Health, Inc. | 2 | $144 |
| Pfizer | 8 | $129 |
| Antares Pharma, Inc. | 8 | $128 |
| Lilly USA, LLC | 8 | $125 |
| Pacira Therapeutics, Inc. | 5 | $108 |
| Boehringer Ingelheim | 4 | $98 |
| Mallinckrodt Enterprises LLC | 2 | $51 |
| AstraZeneca | 2 | $39 |
| Medexus Pharma, Inc. | 2 | $33 |
| Sanofi-aventis U.S. LLC | 2 | $25 |
| Organon | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Bioventus LLC | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$68,122 in reported general payments places this provider in the 90th percentile of 512 rheumatology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 74 | $3,000 |
| Esomeprazole Magnesium | 45 | $1,499 |
| Gabapentin | 32 | $436 |
| Naproxen | 43 | $426 |
| Ibuprofen | 34 | $405 |
| Oxycodone Hcl | 12 | $351 |
| Cyclobenzaprine Hcl | 21 | $214 |
| Carisoprodol | 22 | $175 |
| Omeprazole | 36 | $171 |
| Lisinopril | 14 | $45 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in San Antonio
- Pendleton WickershamSan Antonio$954K
- Thomas RennieSan Antonio$113K
- Kevin KempfSan Antonio$83K
- Jane AyalaSan Antonio$67K
- Pankhuri GuptaSan Antonio$58K
- Fernando SilvaSan Antonio$54K
- John CushDallas$3.7M
- Sanjay ChabraEl Paso$3.3M
- Dhiman BasuColleyville$1.8M
- Frank WellborneNew Braunfels$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.